News

Revolutionary Ginsenoside Redsenol-1 Plus Gains NCI Accreditation

Revolutionary Ginsenoside Redsenol-1 Plus Gains NCI Accreditation

Redsenol-1 Plus Officially Recognized by the National Cancer Institute

Significant Progress in Botanical Therapeutics

Canada Royal Enoch Phytomedicine Ltd., a pioneer in ginseng and ginsenoside research, is thrilled to announce that its innovative supplement, Redsenol-1 Plus Noble Ginsenosides, has achieved a remarkable milestone. This ginsenoside supplement has been incorporated into the National Cancer Institute's (NCI) Drug Dictionary. This recognition emphasizes Canada Royal Enoch Phytomedicine's dedication to enhancing cancer research while highlighting the potential of Redsenol-1 Plus in oncology and supportive care.

Understanding the NCI Drug Dictionary Listing

The NCI Drug Dictionary serves as an outstanding reference for the definitions and synonyms of drugs and agents used for treating cancer and its related conditions. With its recent definition, Redsenol-1 Plus is now categorized as "an oral and herbal supplement containing sixteen ginsenosides derived from ginseng, including rarer monomer forms like Rg3(R, S), Rh1(S, R), and others..." This unique categorization underlines the diverse range of ginsenosides present in Redsenol-1 Plus.

The Unique Features of Redsenol-1 Plus

What sets Redsenol-1 Plus apart from typical ginseng supplements is its composition. Most ginseng extracts primarily provide a smaller range of large-molecule, less absorbable ginsenosides such as Rg1, Rb1, Rd, Re, and Rc. In contrast, Redsenol-1 Plus has a remarkable mix of sixteen bioactive and easily absorbable rare ginsenosides, with a concentration of 20%. This percentage significantly exceeds those of conventional ginseng supplements, which usually only reach about 4% total ginsenosides.

Technological Advances in Ginsenoside Extraction

Canada Royal Enoch Phytomedicine has developed proprietary technologies for the extraction, processing, transformation, and formulation of rare ginsenosides. These state-of-the-art techniques enable the large-scale production of these beneficial compounds, significantly enhancing the company's position as a global leader in ginsenoside innovation and setting it apart from the competition.

Commitment to Research and Scientific Advancement

“The inclusion of Redsenol-1 Plus in the NCI Drug Dictionary offers researchers a standardized definition of its components,” expressed Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine. “We are committed to advancing the scientific understanding of ginsenoside applications in conditions related to cancer through thorough research.”

Ongoing Clinical Trials with Redsenol-1 Plus

In alignment with the recognition from the NCI, Canada Royal Enoch Phytomedicine is also conducting clinical trials aimed at evaluating Redsenol-1 Plus’s effectiveness in addressing cancer-related fatigue—a common and disruptive symptom faced by patients undergoing treatment. This meticulous, triple-blind, placebo-controlled study is being executed by KGK Science, Inc., a prestigious clinical research organization based in Canada. The success of this trial may not only boost understanding of Redsenol-1 Plus but also shape it as a pivotal solution to alleviate cancer-related fatigue.

About Canada Royal Enoch Phytomedicine Ltd.

Canada Royal Enoch Phytomedicine Ltd. stands at the forefront of biotechnology, specializing in the research, production, and sale of natural, plant-based health solutions. The flagship product line, Redsenol (also known as Redsenol-1, Redsenol-1 Plus, and Redsenol DAG), features high-concentration ginsenoside supplements comprising various rare ginsenosides. Through its unique extraction, transformation, and formulation technologies, Canada Royal Enoch Phytomedicine seeks to unlock the complete potential of ginseng and ginsenosides for health and well-being.

Frequently Asked Questions

What is Redsenol-1 Plus?

Redsenol-1 Plus is an oral herbal supplement featuring sixteen ginsenosides derived from ginseng, noted for its potential benefits in cancer care.

How does Redsenol-1 Plus differ from other ginseng products?

Unlike many ginseng extracts that contain low amounts of active ingredients, Redsenol-1 Plus offers a higher concentration of rare and absorbable ginsenosides, making it significantly more effective.

What are the implications of being listed in the NCI Drug Dictionary?

The NCI Drug Dictionary listing provides researchers with an official definition of Redsenol-1 Plus's components, promoting further studies and applications in cancer research.

Is there ongoing research related to Redsenol-1 Plus?

Yes, Canada Royal Enoch is conducting clinical trials to assess the efficacy of Redsenol-1 Plus in mitigating cancer-related fatigue, aiming to provide substantial evidence for its benefits.

Where can I find more information about Canada Royal Enoch Phytomedicine?

For additional details on Canada Royal Enoch Phytomedicine and its product offerings, you can visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading

Top 5 Most Recently Viewed Articles

Jack Henry & Associates Boosts Quarterly Dividend to $.58

Updated Category News Views 98

Jack Henry & Associates Raises Quarterly Dividend Jack Henry & Associates, Inc. (NASDAQ: JKHY) has made a significant announcement regarding its commitment to its shareholders by increasing the quarterly dividend by six percent to $.58 per share. This decision exemplifies the company's dedication to providing value to its stockholders while maintaining a strong financial...

Continue Reading
EXEL Industries Shareholder Update: Voting Rights as of 2025

Updated Category News Views 191

Overview of EXEL Industries EXEL Industries is a renowned French Société Anonyme with a share capital totaling €16,969,750. Located at 54, rue Marcel Paul, 51206 Epernay Cedex, France, the company operates within the framework of the Reims Companies Register (RCS), bearing the number 095 550 356. Current Share and Voting Rights As part of compliance with the...

Continue Reading
ICU Medical Engages in Healthcare Dialogue at Important Conference

Updated Category News Views 120

ICU Medical's Upcoming Participation in a Major Healthcare Conference Exciting developments are on the horizon for ICU Medical, Inc. (Nasdaq: ICUI), a leading innovator in medical technology. The company has announced its participation in an upcoming significant event, the Piper Sandler 37th Annual Healthcare Conference, scheduled in New York City. This event will take...

Continue Reading
Unveil Cherry Blossom Magic at Tokyo Dome Hotel Spring 2025

Updated Category News Views 153

Unveil Cherry Blossom Magic at Tokyo Dome Hotel Spring 2025 Book now and receive up to 50% off during the peak of cherry blossom season Tokyo Dome Hotel, an exquisite venue in the bustling heart of Tokyo, is excited to present a special offer designed for those looking to witness the stunning cherry blossom season. With discounted accommodations of up to 50% off, this...

Continue Reading
Innovative Strategies to Enhance Supply Chain Resilience

Updated Category News Views 101

Enhancing Supply Chain Resilience Through Innovation In today's rapidly changing landscape, Washtenaw Community College (WCC) is set to lead a pivotal discussion on enhancing supply chain resilience. The inaugural Washtenaw Supply Chain Exchange will take place on a notable day, bringing together experts and thought leaders dedicated to navigating the complexities of...

Continue Reading